Program Description:
Non–small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality, with ROS1 rearrangements identifying a small but critical subset of patients. These patients are often younger and non-smokers and face a high risk of central nervous system (CNS) involvement. While the therapeutic landscape has expanded to include multiple generations of tyrosine kinase inhibitors (TKIs), the emergence of complex resistance mechanisms poses a significant challenge to long-term disease control. This session is designed to equip oncology pharmacists with the advanced clinical and operational expertise required to navigate the evolving treatment landscape in ROS1-rearranged NSCLC. Because ROS1 fusions are often mutually exclusive with other oncogenic drivers, comprehensive biomarker testing via next-generation sequencing (NGS) has become an important first step to ensure these alterations are addressed through appropriate treatment selection and prevents the use of less effective, non-targeted therapies. Oncology pharmacists will explore the mechanistic differentiation of first- and next-generation TKI agents while exploring the clinical implications of investigational therapies. By synthesizing evidence from pivotal trials, this session provides a framework for interpreting NGS sequencing data, selecting initial therapy based on CNS burden, and strategically sequencing agents upon progression. Speakers will emphasize the pharmacist's role in institutional leadership from embedding retesting triggers into workflows to proactively managing unique toxicity profiles to optimize patient adherence and outcomes.
Target audience: Oncology Pharmacist
Type of activity: Application
Release date: June 18, 2026
Expiration date: August 18, 2026
Time to complete activity: 1.0 hour
Learner level: Intermediate, Advanced
Fee: Free
Educational
Objectives:
At the completion of this activity, participants will be able to:
- Utilize molecular and resistance testing results to guide evidence-based ROS1-directed treatment planning across lines of therapy
- Apply clinical trial data, CNS activity, and resistance mutation profiles to inform selection and sequencing of ROS1-targeted therapies
- Operationalize mechanism-based toxicity monitoring and management plans for ROS1-targeted therapies to maintain adherence and optimize long-term outcomes
Darren Luon, PharmD, BCOP
Clinical Pharmacy Specialist, Medical Oncology
Yale New Haven Hospital
New Haven, CT
Leila Rostamnjad, PharmD, BCOP
Clinical Pharmacy Manager, Thoracic Oncology and Symptoms Management Clinical Specialist
Dana-Farber Cancer Institute
Boston, Massachusetts
Accreditation Information
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number [UAN TBD]. The activity is available for CE credit through August 18, 2026.
Instructions for Completing the Activity and Receiving CPE Credit
To
receive CPE credit, participants must complete the pretest, review the activity in
its entirety, complete the posttest, and complete the online activity
evaluation. After successful completion of the online activity evaluation, you
can submit your credit to CPE Monitor. You may view your credit within 48 hours
at www.mycpemonitor.net. All participants must request credit before the
activity expiration date. CE credit will not be issued after this date.
Disclosures
Darren Luon, PharmD, BCOP, has no relevant financial relationships with ineligible companies to disclose.
Leila Rostamnjad, PharmD, BCOP, has the following relevant financial relationships with ineligible companies to disclose:
Consultant: Advisory Board Johnson and Johnson for Amivantimab
Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine, RPh, MBA; Rose Buszka, PharmD, BCPS, CHCP; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta have no financial relationships with ineligible companies to disclose.
All of the relevant financial
relationships listed for these individuals have been mitigated.
At least one anonymous peer reviewer has been used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not
constitute any form of professional advice or referral. Discussions concerning
drugs, dosages, and procedures may reflect the clinical experience of the
author(s) or they may be derived from the professional literature or other
sources and may suggest uses that are investigational in nature and not
approved labeling or indications. Participants are encouraged to refer to
primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
Privacy Policy and Terms of Use Information: